



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

 INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	10/003,463
				Filing Date	6 December 2001
				First Named Inventor	Luis Enrique F. Molina
				Group Art Unit	1642
				Examiner Name	Susan N. Ungar
				Confirmation No.	4352
Sheet	1	of	2	Attorney Docket Number	3035-102

U.S. PATENT DOCUMENTS

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code.

⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known			
				Application Number		10/003,463	
				Filing Date		6 December 2001	
				First Named Inventor		Luis Enrique F. Molina	
				Group Art Unit		1642	
				Examiner Name		Susan N. Ungar	
				Confirmation No.		4352	
Sheet	2	of	2	Attorney Docket Number	3035-102		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
		Robert J. Binder, et al., "CD91: a receptor for heat shock protein gp96", Nature Immunology, August 2000, Vol. 1, No. 2, pp. 151-155			T ²
		Marina Celli, et al., "Inflammatory stimuli induced accumulation of MHC class II complexes on dendritic cells", Nature, August 1997, Vol. 388, pp. 782-787			
		Guo-Min Deng, et al., "Synovial cytokine mRNA expression during arthritis triggered by CpG motifs of bacterial DNA", Arthritis Research, 2001, Vol. 3, pp. 48-53			
		Genevieve De Becker, et al., "The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells", International Immunology, Vol. 12, No. 6, pp. 807-815, 2000			
		Francisco Estevez, et al., "Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP)", Vaccine, Vol. 18, 2000, pp. 190-197			
		Eric Hailman, et al., "Lipopolysaccharide (LPS)-binding Protein Accelerates the Binding of LPS to CD14", J. Exp. Med., The Rockefeller University Press, January 1994, Vol. 179, pp. 269-277			
		G. Hartmann, et al., "CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells", Proc. Natl. Acad. Sci. USA, Immunology, August 1999, Vol. 96, pp. 9305-9310			
		Hiroaki Hemmi, et al., "A Toll-like receptor recognizes bacterial DNA", Nature, Vol. 408, December 2000, pp. 740-745			
		Pascale Jeannin, et al., "OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway", Nature Immunology, Vol. 1, No. 6, December 2000, pp. 502-509			
		Isabelle Miconnet, et al., "Cancer Vaccine Design: A Novel Bacterial Adjuvant for Peptide-Specific CTL Induction", The Journal of Immunology, 2001, Vol. 166, pp. 4612-4619			
		Rolando Perez, et al., "Epidermal growth factor receptors in human breast cancer", Breast Cancer Research and Treatment, Vol. 4, 1984, pp. 189-193			
		Yasuaki Tamura, et al., "Immunotherapy of Tumors with Autologous Tumor-Derived Heat Shock Protein Preparations", Science, October 1997, Vol. 278, pp. 117-120			
Examiner Signature				Date Considered	4/6/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.